Sequoia Financial Advisors LLC Purchases 2,474 Shares of Moderna, Inc. (NASDAQ:MRNA)

Sequoia Financial Advisors LLC lifted its position in shares of Moderna, Inc. (NASDAQ:MRNA) by 52.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 7,224 shares of the company’s stock after purchasing an additional 2,474 shares during the quarter. Sequoia Financial Advisors LLC’s holdings in Moderna were worth $718,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Cim Investment Management Inc. lifted its holdings in Moderna by 4.2% during the first quarter. Cim Investment Management Inc. now owns 2,139 shares of the company’s stock worth $329,000 after acquiring an additional 86 shares in the last quarter. Cetera Advisor Networks LLC raised its position in shares of Moderna by 0.5% during the fourth quarter. Cetera Advisor Networks LLC now owns 17,195 shares of the company’s stock worth $3,088,000 after purchasing an additional 87 shares during the period. Ancora Advisors LLC lifted its holdings in shares of Moderna by 41.2% during the 1st quarter. Ancora Advisors LLC now owns 329 shares of the company’s stock valued at $51,000 after purchasing an additional 96 shares in the last quarter. Sunbelt Securities Inc. lifted its holdings in shares of Moderna by 7.5% during the 1st quarter. Sunbelt Securities Inc. now owns 1,428 shares of the company’s stock valued at $211,000 after purchasing an additional 100 shares in the last quarter. Finally, Allworth Financial LP grew its position in shares of Moderna by 6.5% in the 4th quarter. Allworth Financial LP now owns 1,660 shares of the company’s stock valued at $165,000 after purchasing an additional 101 shares during the period. Institutional investors and hedge funds own 75.33% of the company’s stock.

Moderna Stock Down 1.2 %

Shares of MRNA stock opened at $103.86 on Tuesday. Moderna, Inc. has a 52-week low of $62.55 and a 52-week high of $156.75. The company has a quick ratio of 3.36, a current ratio of 3.42 and a debt-to-equity ratio of 0.04. The firm’s 50-day moving average is $99.86 and its 200-day moving average is $93.49.

Moderna (NASDAQ:MRNA) last released its quarterly earnings data on Thursday, February 22nd. The company reported $0.55 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.78) by $1.33. Moderna had a negative return on equity of 10.23% and a negative net margin of 68.84%. The firm had revenue of $2.80 billion for the quarter, compared to analyst estimates of $2.53 billion. During the same quarter in the prior year, the company earned $3.61 earnings per share. The business’s revenue for the quarter was down 44.9% compared to the same quarter last year. As a group, equities research analysts forecast that Moderna, Inc. will post -7.48 EPS for the current fiscal year.

Insider Buying and Selling at Moderna

In other Moderna news, CFO James M. Mock sold 647 shares of the company’s stock in a transaction on Thursday, February 29th. The shares were sold at an average price of $94.57, for a total value of $61,186.79. Following the transaction, the chief financial officer now directly owns 4,300 shares in the company, valued at $406,651. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In other news, CFO James M. Mock sold 647 shares of the business’s stock in a transaction that occurred on Thursday, February 29th. The stock was sold at an average price of $94.57, for a total transaction of $61,186.79. Following the completion of the sale, the chief financial officer now owns 4,300 shares in the company, valued at $406,651. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, President Stephen Hoge sold 2,388 shares of the company’s stock in a transaction that occurred on Thursday, February 29th. The shares were sold at an average price of $94.57, for a total value of $225,833.16. Following the completion of the transaction, the president now directly owns 1,515,898 shares in the company, valued at approximately $143,358,473.86. The disclosure for this sale can be found here. Insiders sold 79,954 shares of company stock valued at $8,407,976 in the last quarter. 15.20% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several brokerages have commented on MRNA. Oppenheimer upgraded shares of Moderna from a “market perform” rating to an “outperform” rating and set a $142.00 target price on the stock in a report on Tuesday, January 2nd. Canaccord Genuity Group boosted their price objective on shares of Moderna from $82.00 to $91.00 and gave the company a “hold” rating in a research report on Friday, February 23rd. Royal Bank of Canada reiterated an “outperform” rating and set a $125.00 target price on shares of Moderna in a report on Thursday, March 28th. HSBC restated a “reduce” rating and issued a $86.00 price target (up from $75.00) on shares of Moderna in a report on Monday, February 26th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Moderna in a report on Thursday, April 11th. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $126.49.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.